Physician profile
John Salazar
NPI 1144244914
$8,047.04
in general payments reported to CMS, 2019-2025
29 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,041 · 2021: $1,638 · 2022: $1,203 · 2023: $970 · 2024: $971 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,621.74 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $903.45 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $821.41 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $753.31 | 2019-2023 | Farxiga |
| Esperion Therapeutics, INC. | $667.04 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $653.63 | 2019-2024 | Jardiance |
| Pfizer INC. | $595.77 | 2019-2024 | |
| Amgen INC. | $467.04 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $296.02 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $242.95 | 2020-2025 | General - Stents, Watchman Flx, Watchman Access System |
| Lexicon Pharmaceuticals, INC. | $215.92 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.24 | 2019-2023 | Lifevest |
| Biotronik INC. | $93.70 | 2019-2020 | |
| Astellas Pharma US INC | $72.05 | 2019-2021 | |
| Abbott Laboratories | $70.63 | 2022-2025 | Mitraclip |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $53.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.98 | 2019 | |
| Medicomp INC | $50.16 | 2023-2024 | Telepatch Cardiac Monitor |
| Nevro Corp. | $38.75 | 2019 | |
| Davol INC. | $30.92 | 2024 | Arista Ah Flexitip |
| Amarin Pharma, INC. | $26.64 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $25.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.68 | 2020-2021 | |
| Medtronic, INC. | $21.35 | 2024 | Cobalt Dr Mri Surescan |
| G Medical Diagnostic Services, INC. | $18.82 | 2020 | |
| Abiomed | $18.69 | 2025 | |
| Daiichi Sankyo INC. | $17.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.42 | 2019 | |
| Coala Life INC | $16.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.